Michael A Cannarile - JoVE Visualize

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Cancer Cell|June 6, 2014

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyCarola H Ries, Michael A Cannarile, Sabine Hoves, et al.

Journal for Immunotherapy of Cancer|May 16, 2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.

Journal for Immunotherapy of Cancer|March 9, 2026

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancersChanghoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.

Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Cancer Cell|June 6, 2014

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapyCarola H Ries, Michael A Cannarile, Sabine Hoves, et al.

Journal for Immunotherapy of Cancer|May 16, 2022

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.

Journal for Immunotherapy of Cancer|March 9, 2026

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancersChanghoon Yoo, Carles Fabregat-Franco, Chia-Chi Lin, et al.

Pageof 3